According to the American Cancer Society a total of 1,660,290 new cancer cases and 580,350 cancer deaths are projected to occur in the United States in 2013. Malignant neoplasms are currently a leading cause of death in the country, second only to cardiovascular diseases. Studies show that one in every four deaths in the U.S. is due to cancer. Even though progress has been made in treatment and care, the number of cancer cases worldwide is expected to increase to 21 million in 2030, causing more than 13 million deaths.
In the face of this major public health
problem, many leading agents, from
the public and private arenas, are engaged in research and
activities aimed at achieving an eventual cure. Federal
R&D Tax Credits are
available to support credit eligible cancer innovation
Enacted in 1981, the federal Research and Development (R&D) Tax Credit allows a credit of up to 13 percent of eligible spending for new and improved products and processes. Qualified research must meet the following four criteria:
Eligible costs include employee wages, cost
of supplies, cost of testing,
contract research expenses, and costs associated with
developing a patent. On January 2, 2013, President Obama
signed the bill extending the R&D
Tax Credit for 2012 and 2013 tax years.
Characterized by the malfunction of genes that control cells growth and division, cancer is a group of diseases marked by the uncontrolled multiplication of abnormal cells that result in the formation of malignant tumors. Medically known as malignant neoplasm, the disease can be caused by both external factors, such as chemicals, radiation, tobacco, and infectious organisms, and internal conditions, namely, hormones, immune conditions, and inherited or metabolic mutations. Risk factors also include obesity, unhealthy dietary habits, lack of physical activities, alcohol use, sexually transmitted HPV-infection, among others.
Most commonly, cancer treatments include a combination of interventions, such as chemotherapy, radiation therapy, and surgery. Biological therapy, targeted therapy, hormone therapy, and palliative care are also available for cancer patients. The choice of treatment is determined by the stage of the disease, in other words, its extent or spread at the time of diagnosis (tumor size and eventual spread to other parts of the body).
According to the World Health Organization
, lung, stomach, liver, colon,
and breast cancers are responsible, in this order, for the
most cancer deaths.
The major cause of death from cancer is denominated
metastasis, a process
through which abnormal cells grow beyond their originating
site, spreading to
other parts of the body.
Cancer research currently involves agents from different spheres. The American Association for Cancer Research is an interesting example of this diversity: with more than 34,000 members, the organization gathers medical centers, laboratories and clinics, government, universities, and industry.
Not only are the origins of innovation initiatives diverse, but so are their nature. In general terms, they can be divided in
For the first group, an interesting example is the recent discovery of more than 70 new susceptibility loci (alterations in genomic regions) for prostate, breast, and ovarian cancers. The Collaborative Oncological Gene-environment Study (COGS)'s findings represent a major step in the characterization of the genetics of cancer and the understanding of inherited susceptibility. The mega-study analyzed more than 200,000 individuals and will allow for the development of more effective preventive initiatives, such as targeted screenings .
Concerning the investigation of treatments, there is a significant number of experimental drugs currently undergoing clinical trials. FierceBiotech recently published a list of "Top 10 Late-Stage Cancer Drugs" , gathering what are considered to be the most promising cancer research programs, based on safety and efficacy data.
In an era of ever-evolving technology, cancer R&D is not restricted to the development of drugs or genetic investigation, comprising a wide range of related innovation. The Wall Street Journal recently presented a promising initiative that aims at using "Big Data" to increase effectiveness of cancer care . A major driver of innovation and job creation, "Big Data" is defined as large data sets that are too large and complex to be analyzed by conventional means . The project, launched by the American Society of Clinical Oncology, will pool patient records in an electronic database allowing doctors to evaluate treatment strategies based on how similar patients nationwide have responded. Even though there are numerous challenges to be overcome, such as patient privacy and data limitations, the potential benefits are enormous since virtually all patients would become contributors to an unprecedented clinical study. This revolutionary access to information is likely to change the face of cancer care and, eventually, medicine.
The revolutionary use of Big Data in cancer diagnosis is also on the horizon. IBM's Watson, a language-proficient computer system initially created to answer questions on the show Jeopardy!, has the ability to assimilate and analyze an enormous quantity of data. Its cumulated "knowledge" includes "more than 600,000 pieces of medical evidence, more than two million pages from medical journals and the further ability to search through up to 1.5 million patient records", an amount of information no human doctor's mind can match. IBM, in partnership with the Memorial Sloan-Kettering Cancer Center in New York and the American private healthcare company WellPoint, is working to enable oncology hospitals, clinics, and individual doctors to rent time with Watson over the cloud. Watson's wider deployment would significantly increase accuracy of diagnoses while simultaneously reducing costs. When tested for lung cancer diagnoses, Watson's success rate was 90%, compared to an average of 50% for human doctors.
Similarly, Brain Mapping activities are
bound to open the way for new
advancements in cancer research. The personalized diagnostics
for brain tumor
patients and the consequent possibility of performing more
figure among the potential benefits. Brain Mapping techniques
damage to language, visual, and motor functions when removing
With a $3 billion U.S. commitment announced in 2013 called BAM
Mapping) and an incredible amount of University research now
occurring in this
domain, one should expect major progress in brain tumor
The world anxiously waits for the end of the affliction of cancer. Genetic discoveries along with drug development and the use of new technology to improve care are examples of advancements due to recent R&D activities. Federal tax credits and funding are available to open the way to more innovation.
Charles R Goulding Attorney/CPA, is the President of R&D Tax Savers.
Andressa Bonafé is a Tax Analyst with R&D Tax Savers.
Charles G Goulding is the Manager of R&D Tax Savers.
|The R&D Tax Credit Aspects of Mechatronics|
|The R&D Tax Credit Aspects of Emotion-Recognition Technology|
|The R&D Tax Credit Aspects of Immunology|
|The R&D Tax Credit Aspects of Arthritis|
|The R&D Tax Credit Aspects of Asthma|
|The R&D Tax Credit Aspects of Telemedicine|
|R&D Tax Credits Enhance Life Science Impact Investing|
|The R&D Tax Credit Aspects of Pediatric Hypertension|
|The R&D Tax Credit Aspects of Parkinsons Disease Technology|
|The R&D Tax Credit Aspects of Legal Medical Marijuana|
|Reaching for the Moon: The R&D Tax Credit Aspects of Conquering Cancer|
|The R&D Tax Credit Aspects of Zika|
|The R&D Tax Aspects of CRISPR-CAS9|
|The R&D Tax Credit Aspects of Bioelectronic Medicine|
|The R&D Tax Credit Aspects of Liquid Biopsy Testing|
|The R&D Tax Credit Aspects of Cryogenics|
|The R&D Tax Aspects of Microbiome Research|
|The R&D Tax Aspects of Mouse Models in Clinical Research|
|The R&D Tax Aspects of Precision Medicine|
|The R&D Tax Aspects of Synthetic Biology|
|The R&D Tax Aspects of Pharmaceutical Packaging|
|New Standards and Regulations Create R&D Tax Credit Opportunities for the Pharmaceutical Packaging Industry|
|The R&D Tax Credit Aspects of Orphan Drugs|
|The R&D Tax Credit Aspects of Blood|
|The R&D Tax Aspects of Regenerative Medicine|
|The R&D Tax Credit Aspects of Environmental Remediation|
|The R&D Tax Credit Aspects of Gastro Technology|
|The R&D Tax Credit Aspects of Multiple Sclerosis|
|The R&D Tax Credit Aspects of Concussion Technology|
|The R&D Tax Credit Aspects of Schizophrenia|
|The R&D Tax Aspects of the New FDA Mobile Apps Requirements|
|The R&D Tax Credit Aspects of the Medical Software Industry|
|The R&D Tax Aspects of Computer Enabled Human Identification|
|The R&D Tax Credit Aspects of Heart Disease|
|The R&D Tax Credit Aspects of Biological Drugs|
|The R&D Tax Credit Aspects of Novel Uses for Genetically Engineered Organisms|
|The R&D Tax Aspects of Respiratory Diseases|
|The R&D Tax Credit Aspects of Cognitive Computing|
|The R&D Tax Credit Aspects of Cosmetics|
|The R&D Tax Credit Aspects of Major Life Science Benefactors|
|The R&D Tax Credit Aspects of the Health Cloud|
|The R&D Tax Credit Aspects of Autism|
|The R&D Tax Credit Aspects of 3D Bioprinting|
|The R&D Credit Aspects of Cell Therapy|
|The R&D Tax Credit Aspects of Sugar Substitution and Reduction in Food Products|
|The R&D Tax Credit Aspects of Gluten-Free Foods|
|R&D Tax Credit Aspects of Sleep Innovation|
|R&D Tax Credit Aspects of Medical Robotics|
|The R&D Tax Aspects of Neuroscience|
|The R&D Tax Credit Aspects of Hearing Technology|
|The R&D Tax Credit Aspects of Eye Disease|
|The R&D Tax Credit Aspects of Dermatology Innovation|
|The R&D Tax Credit Aspects of Bioinformatics|
|The R&D Tax Aspects of Lab Equipment and Instrumentation|
|The R&D Tax Aspects of Salt Reduction|
|The R&D Tax Aspects of Generic Drugs|
|R&D Tax Credit Fundamentals|
|R&D Credits for Companies Combating Superbugs|
|The R&D Tax Credit Aspects of Alzheimers|
|The R&D Tax Aspects of Diabetes|
|The R&D Tax Aspects of Brain Mapping|
|R&D Tax Credit Aspects of Human Body Weight|